Healthcare · Drug Manufacturers - General
Price
$57.52
Market Cap
$117.5B
Employees
34,100
Beta
0.24
Avg Volume
11,349,903
CEO
Christopher S. Boerner
Business Description
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Business History
Price Overview
Last updated: Jun 27, 2026 9:00am (just now)$57.52
+2.13 (+3.85%)
Day Range
$55.40 – $57.73
52-Week Range
$42.52 – $62.89
50-Day MA
$57.09
200-Day MA
$53.80
Volume
23,994,096.00
Analyst Price Targets
Low
$40.00
Consensus
$62.60
High
$75.00
(46 analysts)
Share Structure
Outstanding
2,042,070,000.00
Float
2,038,885,616.00
Free Float
99.8%
High free float
— 99.8% of shares trade freely, ~0.2% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
16.16
Stock Price: $57.52
EPS (Diluted): 3.46
EPS (Diluted): 3.46
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
5.96
Stock Price: $57.52
Total Equity: $18.47B
Shares: 2,041,000,000
Total Equity: $18.47B
Shares: 2,041,000,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
11.08
Market Cap: $117.46B
Total Debt: $45.11B
Cash: $10.21B
EBITDA: $14.55B
Total Debt: $45.11B
Cash: $10.21B
EBITDA: $14.55B
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$147.0B
Market Cap: $117.46B
Total Debt: $45.11B
Cash: $10.21B
Total Debt: $45.11B
Cash: $10.21B
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
67.6%
Gross Profit: $32.60B
Revenue: $48.19B
Revenue: $48.19B
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
26.3%
Operating Income: $12.70B
Revenue: $48.19B
Revenue: $48.19B
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
14.6%
Net Income: $7.05B
Revenue: $48.19B
Revenue: $48.19B
ROE (Profit from shareholder equity)
APINet Income / Total Equity
39.0%
Net Income: $7.05B
Total Equity: $18.47B
Total Equity: $18.47B
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
13.5%
Operating Income: $12.70B
Tax Rate: 24.4%
Equity: $18.47B
Total Debt: $45.11B
Cash: $10.21B
Tax Rate: 24.4%
Equity: $18.47B
Total Debt: $45.11B
Cash: $10.21B
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.26
Current Assets: $29.39B
Current Liabilities: $23.42B
Current Liabilities: $23.42B
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
2.44
Short-Term Debt: $2.26B
Long-Term Debt: $42.85B
Total Debt: $45.11B
Total Equity: $18.47B
Long-Term Debt: $42.85B
Total Debt: $45.11B
Total Equity: $18.47B
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$23.61
Revenue: $48.19B
Shares: 2,041,000,000
Shares: 2,041,000,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$9.05
Total Equity: $18.47B
Shares: 2,041,000,000
Shares: 2,041,000,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$6.29
Operating CF: $14.16B
CapEx: -$1.31B
Shares: 2,041,000,000
CapEx: -$1.31B
Shares: 2,041,000,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
4.6%
Last Dividend: N/A
Stock Price: $57.52
Stock Price: $57.52
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $7.05B
Net Income: $7.05B
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares BMY against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 25, 2026 3:02am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B |
| Cost of Revenue | $19.6B | $19.7B | $19.6B | $20.9B | $15.6B |
| Gross Profit | $26.8B | $26.5B | $25.4B | $27.4B | $32.6B |
| Operating Expenses | $17.2B | $17.2B | $16.9B | $17.8B | $19.9B |
| Operating Income | $9.5B | $9.3B | $8.5B | $9.7B | $12.7B |
| Net Income | $7.0B | $6.3B | $8.0B | -$8.9B | $7.1B |
| EBITDA | $20.1B | $19.2B | $19.4B | $3.2B | $14.5B |
| EPS | $3.15 | $2.97 | $3.88 | $-4.41 | $3.46 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 8:12pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $14.0B | $9.1B | $11.5B | $10.3B | $10.2B |
| Total Current Assets | $33.3B | $27.3B | $31.8B | $29.8B | $29.4B |
| Total Assets | $109.3B | $96.8B | $95.2B | $92.6B | $90.0B |
| Current Liabilities | $21.9B | $21.9B | $22.3B | $23.8B | $23.4B |
| Long-Term Debt | $39.6B | $35.1B | $36.7B | $47.6B | $42.9B |
| Total Liabilities | $73.3B | $65.7B | $65.7B | $76.2B | $71.5B |
| Total Equity | $35.9B | $31.1B | $29.4B | $16.3B | $18.5B |
| Retained Earnings | $23.8B | $25.5B | $28.8B | $14.9B | $16.9B |
Cash Flow (Annual)
Last updated: Jun 25, 2026 3:02am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $16.2B | $13.1B | $13.9B | $15.2B | $14.2B |
| Capital Expenditure | -$973.0M | -$1.1B | -$1.2B | -$1.2B | -$1.3B |
| Free Cash Flow | $15.2B | $11.9B | $12.7B | $13.9B | $12.8B |
| Acquisitions (net) | -$862.0M | -$3.0B | -$260.0M | -$20.7B | -$2.9B |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$6.3B | -$8.0B | -$5.2B | $0 | $0 |
| Net Change in Cash | -$657.0M | -$5.0B | $2.2B | -$1.2B | -$137.0M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 9:00am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$46.3B $45.3B – $47.6B
|
$41.0B $41.0B – $41.0B
|
$37.4B $36.8B – $38.0B
|
$36.7B $36.1B – $37.2B
|
| EBITDA |
$15.3B $14.9B – $15.7B
|
$13.5B $13.5B – $13.5B
|
$12.3B $12.1B – $12.5B
|
$12.1B $11.9B – $12.3B
|
| Net Income |
$12.4B $11.2B – $13.5B
|
$9.1B $8.2B – $13.0B
|
$9.9B $9.7B – $10.1B
|
$9.7B $9.5B – $9.9B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 25, 2026 3:02am (2d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -0.5% | -2.5% | +7.3% | -0.2% |
| Gross Profit Growth | -1.0% | -4.3% | +8.2% | +18.8% |
| Operating Income Growth | -2.8% | -8.6% | +14.0% | +31.5% |
| Net Income Growth | -9.5% | +26.8% | -211.5% | +178.8% |
| EBITDA Growth | -4.5% | +0.8% | -83.6% | +359.1% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-15 | Haller Julia A | M-Exempt | 20,460.00 | $53.76 | $1.1M |
| 2026-06-15 | Haller Julia A | M-Exempt | 20,460.00 | $53.76 | $1.1M |
| 2026-06-03 | Short Bartie Wendy | M-Exempt | 8,040.00 | $0.00 | $0 |
| 2026-06-03 | Short Bartie Wendy | F-InKind | 3,876.00 | $54.72 | $212,095 |
| 2026-06-03 | Short Bartie Wendy | M-Exempt | 8,040.00 | $0.00 | $0 |
| 2026-05-01 | Lenkowsky Adam | M-Exempt | 1,373.00 | $0.00 | $0 |
| 2026-05-01 | Lenkowsky Adam | J-Other | 203.00 | $0.00 | $0 |
| 2026-05-01 | Lenkowsky Adam | F-InKind | 599.00 | $58.22 | $34,874 |
| 2026-05-01 | Lenkowsky Adam | M-Exempt | 1,373.00 | $0.00 | $0 |
| 2026-04-01 | Shanahan Karin | M-Exempt | 3,307.00 | $0.00 | $0 |
| 2026-04-01 | Shanahan Karin | F-InKind | 1,692.00 | $61.73 | $104,447 |
| 2026-04-01 | Shanahan Karin | M-Exempt | 3,307.00 | $0.00 | $0 |
| 2026-04-01 | Elkins David V | S-Sale | 25,519.00 | $61.60 | $1.6M |
| 2026-04-01 | Elkins David V | S-Sale | 4,481.00 | $62.05 | $278,046 |
| 2026-03-31 | YALE PHYLLIS R | A-Award | 577.08 | $0.00 | $0 |
| 2026-03-31 | Samuels Theodore R. II | A-Award | 845.01 | $0.00 | $0 |
| 2026-03-31 | Rice Derica W | A-Award | 638.91 | $0.00 | $0 |
| 2026-03-31 | McMullen Michael R. | A-Award | 577.08 | $0.00 | $0 |
| 2026-03-31 | Arduini Peter J | A-Award | 577.08 | $0.00 | $0 |
| 2026-03-10 | Hickey Benjamin | A-Award | 17,143.00 | $0.00 | $0 |
Dividend History (Last 20)
Last updated: Jun 24, 2026 8:12pm (2d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-07-02 | $0.63 | 2026-06-17 | 2026-07-02 | 2026-08-03 |
| 2026-04-02 | $0.63 | 2026-03-02 | 2026-04-02 | 2026-05-01 |
| 2026-01-02 | $0.63 | 2025-12-10 | 2026-01-02 | 2026-02-02 |
| 2025-10-03 | $0.62 | 2025-09-17 | 2025-10-03 | 2025-11-03 |
| 2025-07-03 | $0.62 | 2025-06-17 | 2025-07-03 | 2025-08-01 |
| 2025-04-04 | $0.62 | 2025-03-03 | 2025-04-04 | 2025-05-01 |
| 2025-01-03 | $0.62 | 2024-12-11 | 2025-01-03 | 2025-02-03 |
| 2024-10-04 | $0.60 | 2024-09-10 | 2024-10-04 | 2024-11-01 |
| 2024-07-05 | $0.60 | 2024-06-18 | 2024-07-05 | 2024-08-01 |
| 2024-04-04 | $0.60 | 2024-03-01 | 2024-04-05 | 2024-05-01 |
| 2024-01-04 | $0.60 | 2023-12-06 | 2024-01-05 | 2024-02-01 |
| 2023-10-05 | $0.57 | 2023-09-20 | 2023-10-06 | 2023-11-01 |
| 2023-07-06 | $0.57 | 2023-06-14 | 2023-07-07 | 2023-08-01 |
| 2023-04-06 | $0.57 | 2023-03-03 | 2023-04-10 | 2023-05-01 |
| 2023-01-05 | $0.57 | 2022-12-08 | 2023-01-06 | 2023-02-01 |
| 2022-10-06 | $0.54 | 2022-09-14 | 2022-10-07 | 2022-11-01 |
| 2022-06-30 | $0.54 | 2022-06-15 | 2022-07-01 | 2022-08-01 |
| 2022-03-31 | $0.54 | 2022-03-01 | 2022-04-01 | 2022-05-02 |
| 2022-01-06 | $0.54 | 2021-12-13 | 2022-01-07 | 2022-02-01 |
| 2021-09-30 | $0.49 | 2021-09-09 | 2021-10-01 | 2021-11-01 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for BMY — it's generated by the pipeline (
market-narrative step).
No community reviews yet for BMY.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30